1. Home
  2. ASTH vs NUVB Comparison

ASTH vs NUVB Comparison

Compare ASTH & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Astrana Health Inc.

ASTH

Astrana Health Inc.

HOLD

Current Price

$35.76

Market Cap

1.9B

ML Signal

HOLD

Logo Nuvation Bio Inc.

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$6.60

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASTH
NUVB
Founded
1994
2018
Country
United States
United States
Employees
N/A
307
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.0B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
ASTH
NUVB
Price
$35.76
$6.60
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
8
Target Price
$34.86
$11.38
AVG Volume (30 Days)
531.5K
6.1M
Earning Date
05-07-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.29
N/A
Revenue
$519,907,752.00
N/A
Revenue This Year
$27.38
$203.82
Revenue Next Year
$10.78
$58.18
P/E Ratio
$117.69
N/A
Revenue Growth
45.90
N/A
52 Week Low
$18.08
$2.18
52 Week High
$51.60
$9.75

Technical Indicators

Market Signals
Indicator
ASTH
NUVB
Relative Strength Index (RSI) 26.36 49.95
Support Level $20.42 $5.28
Resistance Level $34.49 $6.13
Average True Range (ATR) 1.96 0.39
MACD -0.88 -0.06
Stochastic Oscillator 1.77 27.03

Price Performance

Historical Comparison
ASTH
NUVB

About ASTH Astrana Health Inc.

Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: